Overview
Estradiol is the main estrogen produced by the human ovary during the reproductive years. The medicine is a laboratory-made version of that hormone, and it is one of the most widely prescribed estrogens in the world. It is used mainly to ease the symptoms of menopause, to replace estrogen when the body cannot make enough, and in a few other specific situations described below. It comes in many forms: tablets, skin patches, gels, a spray, vaginal creams, vaginal inserts and a vaginal ring. Each form delivers the hormone differently, and each suits different needs.
This page explains what estradiol is, how it works, how the different products are typically used, what side effects and risks are recognised, and which medicines can interact with it. It is written to help you understand a medicine you have been prescribed or are trying to identify. It is not a substitute for the advice of the clinician or pharmacist who knows your health history.
A note on names. Estradiol is sold on its own under brand names such as Estrace (tablets), Vagifem and Yuvafem (vaginal inserts), Climara, Vivelle-Dot, Minivelle and Menostar (patches), EstroGel, Divigel and Elestrin (gels), Evamist (spray) and Estring (vaginal ring). It is also combined with other hormones in products such as Activella, Amabelz, Mimvey and Lopreeza (estradiol with norethindrone acetate), Angeliq (estradiol with drospirenone), Prefest (estradiol with norgestimate), Bijuva (estradiol with progesterone) and Natazia (estradiol valerate with dienogest). Many generic versions are labeled simply as estradiol.
The brand list on file for this drug also includes a large number of birth control pills, such as Yaz, Yasmin, Sprintec, Loestrin and Seasonique. These contain ethinyl estradiol, which is a different, synthetic estrogen with its own properties and its own labeling. This page is about estradiol itself, not those contraceptives. Some homeopathic liquids and drops also carry the name estradiol in highly diluted form. They are not the same as the prescription medicines described here and are not approved by the FDA for treating menopause or any other condition.
Uses
Estradiol products are approved for a defined group of uses. Which ones apply depends on the form of the product.
Menopausal symptoms. The most common use is the treatment of moderate to severe vasomotor symptoms, meaning hot flashes and night sweats, that come with menopause. Oral tablets, patches, gels, the spray and some combination products are used for this purpose. Hot flashes are the symptom that estrogen treats most reliably, and estradiol is one of the most effective options for them.
Vulvar and vaginal atrophy. Falling estrogen levels thin and dry the tissues of the vagina and vulva. This can cause dryness, burning, irritation, pain during intercourse and a higher rate of urinary symptoms. Low-dose vaginal estradiol (creams, inserts and the ring) is aimed mainly at these local symptoms. Because only a small amount reaches the bloodstream, these products are often chosen when vaginal symptoms are the only complaint. Oral, patch and gel products also treat these symptoms, although they are not always enough on their own.
Low estrogen from other causes. Tablets are approved for hypoestrogenism due to hypogonadism, removal of the ovaries (castration) or primary ovarian failure. In these situations, estradiol replaces a hormone the body is not producing, often in younger people, and treatment can continue for years under specialist supervision.
Prevention of postmenopausal osteoporosis. Estrogen slows bone loss after menopause. Some estradiol products carry this indication, including the low-dose weekly patch Menostar, which is specifically intended for bone protection. Because of the risks discussed below, estrogen is generally considered for bone protection mainly when a person also needs it for menopausal symptoms, or when other bone medicines are not suitable. Medicines such as alendronate and raloxifene are among the alternatives clinicians weigh.
Cancer palliation. Oral estradiol is also labeled for the palliative treatment of certain cases of metastatic breast cancer and of advanced androgen-dependent prostate cancer. These are specialist uses, now less common because newer treatments exist.
Estradiol is also widely used outside its labeled indications, particularly in gender-affirming hormone therapy for transgender women and nonbinary people. In that setting it is prescribed and monitored by clinicians experienced in this care, and the dosing and monitoring differ from menopausal use. Information on this page about labeled uses should not be read as covering that application in detail.
How estradiol works
Estradiol acts by binding to estrogen receptors, which sit inside cells in many tissues, including the uterus, vagina, breast, bone, brain, blood vessels and liver. Once bound, the hormone-receptor complex moves to the cell nucleus and changes the activity of particular genes. This is why estrogen has such wide-ranging effects: it helps maintain the lining of the vagina and urinary tract, supports bone by restraining the cells that break it down, influences cholesterol handling in the liver, affects blood clotting proteins and acts on the temperature-regulating centres of the brain.
Hot flashes are thought to occur because falling estrogen narrows the range of body temperature the brain tolerates before triggering heat-loss responses. Replacing estrogen widens that range again, so flushing and sweating episodes become less frequent and less intense.
Estradiol also feeds back on the pituitary gland, lowering the release of the hormones LH and FSH. This feedback is why, in a person with ovaries, estrogen therapy can alter natural cycles, and why estradiol has a role in some hormone-suppressing treatments.
In the body, estradiol is interconverted with estrone, a weaker estrogen, and both can be bound to a carrier protein called sex hormone-binding globulin or converted to inactive sulfate forms. When estradiol is swallowed, much of it is metabolised in the gut wall and liver on its first pass, so oral dosing produces a high estrone-to-estradiol ratio and a noticeable effect on liver-made proteins. Skin patches, gels and sprays deliver estradiol directly into the circulation and largely bypass this first-pass effect. This difference is the main reason clinicians sometimes prefer a transdermal product for people with certain risk factors, such as raised triglycerides or a higher baseline risk of blood clots. Observational studies suggest that standard-dose transdermal estradiol carries a lower risk of venous blood clots than oral estrogen, although this has not been confirmed in large randomised trials.
Forms, strengths and identification
Estradiol is available in a wider variety of dosage forms than most medicines. The forms on record for this drug include tablets (including film-coated and coated tablets), capsules, transdermal patches, extended-release patches, gels (including metered-dose pump gels), a topical spray, vaginal creams, vaginal inserts that are placed with an applicator, and a vaginal ring system. Combination products add a second hormone, usually a progestin, to the same tablet or patch.
Tablets. Oral estradiol tablets are commonly made in strengths of 0.5 mg, 1 mg and 2 mg. Manufacturers often use different colours to tell strengths apart, and the tablets are typically round and sometimes scored. Colours and imprints vary from one manufacturer to another, so a colour alone is not a reliable way to identify a tablet. If you are trying to identify a pill, look at the imprint code on the tablet and compare it with a trusted database or ask a pharmacist. More than a thousand pill listings relate to estradiol-containing products, so several different tablets can look alike.
Patches. Patches are described by how much estradiol they release per day, typically in the range of roughly 0.014 mg to 0.1 mg per day. Some are changed twice weekly and others once weekly, depending on the brand. Menostar is a low-dose weekly patch aimed at bone protection.
Gels and spray. Gels such as EstroGel, Divigel and Elestrin are applied to the skin once daily, and the product comes as a metered pump or single-use packets. Evamist is a metered spray applied to the inner forearm.
Vaginal products. Vaginal estradiol cream is supplied in a tube with a marked applicator and is available at a low concentration of 0.01%. Vaginal inserts such as Vagifem and Yuvafem contain a very small amount, 10 micrograms, and are placed with a single-use applicator. Estring is a flexible ring that sits in the vagina and releases a steady low amount of estradiol over about three months.
Combination products. These contain estradiol together with norethindrone acetate, drospirenone, norgestimate or progesterone. The added progestin is there to protect the uterine lining. Natazia combines estradiol valerate (an ester form of estradiol) with dienogest and is used as a contraceptive. Oriahnn combines elagolix, estradiol and norethindrone for heavy menstrual bleeding caused by uterine fibroids.
Dosage & administration
Estradiol dosing is individualised. The general principle, stated in the labeling of all estrogen products, is to use the lowest effective dose for the shortest time that meets the treatment goals, and to reassess periodically whether treatment is still needed. The details below describe typical patterns only. Your prescriber and the product label determine what applies to you.
Oral tablets. Tablets are generally taken once daily, with or without food, at about the same time each day. For menopausal symptoms, clinicians commonly begin with a low strength and adjust according to how symptoms respond. Some regimens are cyclic, with estrogen taken for around three weeks followed by a week without it, while others are continuous. Cyclic schedules were once routine, but continuous use is now common, particularly when a progestin is also prescribed. For hypoestrogenism due to hypogonadism or ovarian failure, a prescriber may use a different schedule, including slow dose increases in younger patients.
Patches. A patch is applied to clean, dry, intact skin on the lower abdomen or buttocks, and not on the breasts. The site is usually rotated with each new patch so the same area of skin is not used again for a week or two. Depending on the product, a patch stays in place for either three to four days or seven days. Patches that loosen can sometimes be pressed back down. If one comes off, the product leaflet explains what to do.
Gels and spray. Gels are applied once daily to a designated area, such as the arm or thigh, and allowed to dry completely before dressing. Skin-to-skin contact with another person, especially a child, should be avoided until the gel has dried, because estradiol can transfer. Many labels advise covering the application area with clothing. The spray is applied to the forearm and left to dry. Sunscreen and showering timing are covered in each product's instructions, and these differ between products.
Vaginal cream. The label for the 0.01% cream describes a regimen in which a higher amount is used daily for one or two weeks, then reduced, and finally a maintenance schedule of one to three times a week once the vaginal tissue has recovered. The amount is measured using the marked applicator, and the number of doses per tube varies. The labeling emphasises choosing the lowest dose and regimen that controls symptoms and stopping as soon as possible.
Vaginal inserts and ring. Inserts are typically used daily for the first two weeks and then twice a week as maintenance. The ring is placed by the patient or a clinician, left in for about 90 days, and then replaced.
Added progestin. People who still have a uterus and use systemic estrogen (tablets, patches, gels, spray) are usually prescribed a progestin or progesterone as well, because unopposed estrogen thickens the uterine lining and increases the risk of endometrial cancer. People who have had a hysterectomy generally do not need one. Low-dose vaginal products are handled differently, and the need for a progestin with them is less clear-cut; prescribers decide this case by case.
Missed doses and stopping. A missed tablet is usually taken when remembered unless the next dose is close, and doses are not doubled, but the patient leaflet or a pharmacist can give product-specific advice. Estradiol is often tapered or stopped on a clinician's schedule, and symptoms such as hot flashes can return, sometimes after a period of weeks or months.
Warnings
Estrogen medicines carry several well-documented risks. Much of what is known comes from the Women's Health Initiative (WHI), a large US research programme that studied oral conjugated estrogens, alone or with the progestin medroxyprogesterone acetate, in postmenopausal women. The labeling for estradiol products applies those findings broadly, on the assumption that risks are likely to be similar for other estrogens, doses and forms, although direct data are limited.
Endometrial cancer. In a person with a uterus, estrogen taken without a progestin raises the risk of endometrial hyperplasia and endometrial cancer, and the risk increases with the dose and the length of use. Adding a progestin lowers this risk. Any unexpected or persistent vaginal bleeding in a postmenopausal person needs medical evaluation, which may include sampling of the uterine lining, to look for malignancy.
Cardiovascular disease and blood clots. In the WHI, estrogen-alone therapy was linked to a higher risk of stroke and deep vein thrombosis. Estrogen plus progestin was linked to higher risks of deep vein thrombosis, pulmonary embolism, stroke and heart attack. Estrogen should not be used to prevent heart disease. The risk depends on age, time since menopause and individual factors, and it is considered to be lower in younger people beginning treatment close to menopause than in those who start later in life.
Breast cancer. The estrogen-plus-progestin arm of the WHI showed an increased risk of invasive breast cancer with longer-term use. The estrogen-alone arm did not show the same increase over its study period. Regular breast examination and mammography as recommended for one's age remain important during treatment.
Dementia. In a WHI memory study, women aged 65 or older who took estrogen, with or without a progestin, had a higher risk of developing probable dementia. It is unknown whether this applies to younger postmenopausal women. Estrogen is not used to prevent dementia.
Other cautions. The labeling also describes the following concerns:
- Gallbladder disease, including gallstones needing surgery, is more common among estrogen users, particularly with oral products.
- Estrogens can sharply raise triglycerides in people who already have very high levels, which can in turn lead to pancreatitis.
- Blood pressure can rise in some users, so it should be checked periodically.
- Fluid retention can aggravate conditions such as heart or kidney problems, asthma, epilepsy and migraine, and these are watched more closely during treatment.
- Sudden loss of vision, double vision or the onset of migraine may signal a blood vessel problem in the eye or brain and needs urgent attention.
- In people with hereditary angioedema, estrogens can trigger or worsen swelling attacks.
- Estrogens can worsen endometriosis, uterine fibroids, porphyria and lupus in some people.
- Calcium levels need monitoring in people with breast cancer and bone involvement, because estrogens can raise calcium.
- Estrogens raise thyroid-binding protein, which may change thyroid medicine needs.
Surgery that involves prolonged immobilisation raises clot risk, and prescribers sometimes advise pausing estrogen beforehand. Smoking adds to cardiovascular risk. Clinicians generally advise reviewing the need for estrogen at least yearly. People using the vaginal products are advised that, although absorption is low, the class warnings still appear on the labels.
For more general consumer-oriented reading, MedlinePlus Drug Information provides plain-language summaries of estrogen products.
Contraindications
Labeling for estradiol products lists conditions in which they should not be used. These generally include:
- undiagnosed abnormal genital bleeding;
- known, suspected or past breast cancer, with limited exceptions for the cancer-palliation use;
- known or suspected estrogen-dependent tumours;
- active deep vein thrombosis or pulmonary embolism, or a history of them;
- active or past arterial thromboembolic disease, such as stroke or heart attack;
- known liver dysfunction or liver disease;
- known protein C, protein S or antithrombin deficiency, or other known clotting disorders;
- known or suspected pregnancy;
- a previous anaphylactic reaction or angioedema to the product.
Anyone who has had an allergic reaction to an estrogen product, or to an ingredient in a patch adhesive, gel base or tablet filler, should discuss it with a prescriber before starting. Some tablets contain lactose, and some contain dyes that are less well tolerated by sensitive individuals.
Side effects
Many people use estradiol without problems, and side effects often ease within the first weeks or months as the body adjusts. Reactions reported most often include:
- headache, including migraine;
- breast pain or tenderness;
- irregular vaginal bleeding or spotting, especially in the first months;
- abdominal cramping or bloating;
- nausea;
- hair loss;
- fluid retention and swelling;
- mood changes;
- leg cramps.
Vaginal products can cause local irritation, discharge and yeast infections (vaginal candidiasis). Patches and gels can cause skin redness, itching or a rash at the site. Adhesive from patches can leave residue, and a patch may not stick well in hot weather or after swimming. Some people notice that breast tenderness and spotting settle once a dose is adjusted, or when changing from an oral form to a patch.
Other reported effects include raised blood pressure, abnormal liver function tests, enlargement of uterine fibroids, changes in libido, contact lens intolerance from changes in corneal curvature, and cholestatic jaundice.
Serious risks are those described under Warnings: endometrial and breast cancer, stroke, heart attack, venous blood clots, gallbladder disease and probable dementia. Symptoms that call for prompt medical attention include chest pain, sudden shortness of breath, coughing blood, severe headache, sudden vision changes, slurred speech, weakness on one side of the body, pain or swelling in one leg, a breast lump, yellowing of the skin or eyes, and unusual or heavy vaginal bleeding. A pharmacist or doctor can help you tell ordinary adjustment effects from signs that need review.
Drug interactions
Estradiol is broken down largely by liver enzymes, especially CYP3A4, so medicines that speed up or slow down these enzymes can change estradiol levels. Interactions are most relevant with oral estradiol, but they can also occur with other forms.
Medicines that may lower estradiol levels and weaken its effect. Enzyme inducers include rifampin, carbamazepine, phenytoin, phenobarbital and primidone. The herbal supplement St. John's wort works the same way. With these, symptoms such as hot flashes or breakthrough bleeding may appear, and a prescriber may adjust treatment.
Medicines that may raise estradiol levels. CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, ritonavir and some other HIV protease inhibitors, can increase estradiol exposure. Grapefruit juice can have a similar effect in large amounts.
Thyroid hormone. Oral estrogen raises thyroid-binding globulin, which can bind more of the thyroid hormone in the blood. People who take levothyroxine for an underactive thyroid may need a higher dose after starting oral estradiol, and thyroid tests are often rechecked. Transdermal estradiol has less effect on this.
Anticoagulants and clotting. Estrogens can change the levels of several clotting factors, which may alter the response to warfarin, so closer monitoring of clotting tests may be needed when estradiol is started or stopped.
Other medicines. Estrogens may reduce blood levels of lamotrigine (mainly an issue with ethinyl estradiol, but it is sometimes relevant here too) and may affect the levels of immunosuppressants such as cyclosporine and tacrolimus. Taking estradiol together with other hormonal medicines, such as tamoxifen or raloxifene, is an area where specialist advice matters. Combining estrogen with another estrogen product, such as conjugated estrogens, is not usually done.
Laboratory tests. Estradiol can alter the results of some blood tests. It can shorten clotting times and raise several clotting factors, raise total thyroid hormone measurements while leaving free thyroid hormone unchanged, raise binding proteins for cortisol and sex hormones, raise HDL cholesterol, lower LDL cholesterol, raise triglycerides, and impair glucose tolerance. Anyone having laboratory tests should mention that they use estrogen.
Because many prescription, over-the-counter and herbal products can interact, a pharmacist can check your full medication list.
Pregnancy & breastfeeding
Estradiol is not indicated for use during pregnancy, and the labeling lists known or suspected pregnancy as a reason not to use it. There is no benefit in pregnancy, and a person who becomes pregnant while using it is generally advised to speak to their clinician promptly. Menopausal and cancer-palliation uses do not normally arise during pregnancy. In contrast, estradiol-containing contraceptives and some combination products are designed for people who may be fertile and have their own labeling.
Estrogens pass into breast milk in small amounts. Estrogen use during breastfeeding has been associated with a decrease in the quantity and quality of milk. For that reason, treatment is generally discussed with a clinician before use by someone who is nursing, and the benefits and risks to both parent and infant are weighed.
Pediatric use
Estradiol is not used for menopausal symptoms in children and is not approved for general paediatric use. It is, however, prescribed by paediatric endocrinologists in specific circumstances, such as inducing puberty in girls with ovarian failure or conditions like Turner syndrome. In these cases doses start very low and increase gradually to mimic natural puberty.
Estrogens influence bone growth, and high or prolonged exposure before growth is complete can close the growth plates early and limit final height. Bone age and growth are therefore monitored. Children should not be exposed accidentally to gels or sprays. Contact with a treated adult's skin has been reported to cause breast enlargement and other signs of estrogen exposure in children, so careful handling and storage are emphasised.
Older-adult use
Older adults are more sensitive to several of the risks associated with systemic estrogen. The WHI memory study found an increased risk of probable dementia in women aged 65 and older, and cardiovascular and clot risks rise with age and with the number of years since menopause. For this reason, guidance for older adults generally advises against starting oral or transdermal estrogen for prevention of chronic disease, and favours the lowest effective dose for the shortest time when it is used for symptoms.
Low-dose vaginal estradiol is treated differently, because very little reaches the bloodstream. Geriatric guidance generally considers it a reasonable option for vaginal dryness, pain with intercourse and certain recurrent urinary tract infections. Older people who continue estrogen for many years are usually reviewed regularly, including blood pressure, breast screening and a discussion of whether it is still needed.
Kidney & liver impairment
Liver. The liver metabolises estradiol and produces many estrogen-sensitive proteins. Known liver dysfunction or disease is a listed contraindication, and a history of cholestatic jaundice, including jaundice associated with pregnancy or earlier estrogen use, calls for caution. Estrogens may also worsen gallbladder disease. Because transdermal products bypass the first pass through the liver, a prescriber may consider them in selected cases of milder liver concerns, but the contraindication still applies where liver disease is established.
Kidneys. Estradiol is not specifically contraindicated in kidney disease, and no particular dose changes are mandated by the labeling. But because estrogens can cause fluid retention, they are used with care in people with significant kidney impairment, and monitoring is advised. Dose decisions are individualised by the prescriber.
Overdose
A single large ingestion of estrogen, including accidental ingestion by a child, rarely causes serious harm. Reported effects of overdose include nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment consists of stopping the product and providing symptomatic care. Anyone who suspects an overdose, or a child who has swallowed or been exposed to a product, should contact a poison control centre or emergency service for guidance rather than waiting for symptoms.
Storage and handling
Estradiol tablets, patches, gels and vaginal products are generally stored at room temperature, away from excess heat, moisture and direct sunlight, and out of the reach of children and pets. Patches should be kept in their sealed pouches until used, and used patches should be folded with the sticky sides together and disposed of so children and animals cannot reach them. Gels and sprays are flammable until they dry because of their alcohol content, so heat and open flames should be avoided at the time of application. Specific storage conditions are printed on each product's packaging and may differ from one brand to another.
Alternatives and related treatments
Other options exist for the same problems. For hot flashes, non-hormonal choices include certain antidepressants such as paroxetine and venlafaxine, gabapentin, and a newer neurokinin-receptor blocker called fezolinetant. For vaginal symptoms, non-hormonal moisturisers and lubricants, or vaginal DHEA (prasterone) and ospemifene, are used. Other estrogens, such as conjugated estrogens, and progestogens, such as progesterone, medroxyprogesterone and norethindrone, are used in menopausal hormone therapy. The choice among these depends on symptoms, medical history, personal preference and risk factors. The National Institutes of Health publishes background information on menopausal hormone therapy for the general public.